{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T05:38:11Z","timestamp":1775367491473,"version":"3.50.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2014-083"],"award-info":[{"award-number":["2014-083"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","award":["EMH-D5268"],"award-info":[{"award-number":["EMH-D5268"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010648","name":"Universitaire Ziekenhuizen Leuven, KU Leuven","doi-asserted-by":"publisher","award":["RT0817"],"award-info":[{"award-number":["RT0817"]}],"id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Microenvironment"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12307-018-00219-5","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T17:54:04Z","timestamp":1548352444000},"page":"3-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Tumor Microenvironment in Post-Transplant Lymphoproliferative Disorders"],"prefix":"10.1007","volume":"12","author":[{"given":"Lukas","family":"Marcelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-1086","authenticated-orcid":false,"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"219_CR1","unstructured":"Swerdlow S (2017) Post-transplant lymphoproliferative diorders. In: Swerdlow S (ed) WHO classification of Tumours of Haematopoietic and lymphoid tissues, revised 4t. Lyon, pp 453\u2013462"},{"key":"219_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/150835","volume":"2013","author":"J Morscio","year":"2013","unstructured":"Morscio J, Dierickx D, Tousseyn T (2013) Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol 2013:1\u201313. \n                    https:\/\/doi.org\/10.1155\/2013\/150835","journal-title":"Clin Dev Immunol"},{"key":"219_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","volume":"378","author":"D Dierickx","year":"2018","unstructured":"Dierickx D, Habermann T (2018) Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378:549\u2013562","journal-title":"N Engl J Med"},{"key":"219_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/00000478-200005000-00013","volume":"24","author":"JD Nuckols","year":"2000","unstructured":"Nuckols JD, Baron PW, Stenzel TT, Olatidoye BA, Tuttle-Newhall JE, Clavien PA, Howell DN (2000) The pathology of liver-localized post-transplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol 24:733\u2013741","journal-title":"Am J Surg Pathol"},{"key":"219_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14:517\u2013534. \n                    https:\/\/doi.org\/10.1038\/nrc3774","journal-title":"Nat Rev Cancer"},{"key":"219_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00054","volume":"8","author":"T Menter","year":"2018","unstructured":"Menter T, Tzankov A (2018) Mechanisms of immune evasion and immune modulation by lymphoma cells. Front Oncol 8:1\u201311. \n                    https:\/\/doi.org\/10.3389\/fonc.2018.00054","journal-title":"Front Oncol"},{"key":"219_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","volume":"65","author":"C Belli","year":"2018","unstructured":"Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, Curigliano G (2018) Targeting the microenvironment in solid tumors. Cancer Treat Rev 65:22\u201332. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2018.02.004","journal-title":"Cancer Treat Rev"},{"key":"219_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","volume":"11","author":"R Reshef","year":"2011","unstructured":"Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA, Tsai DE (2011) Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 11:336\u2013347. \n                    https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03387.x","journal-title":"Am J Transplant"},{"key":"219_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaci.2005.05.038","volume":"116","author":"DA Thorley-Lawson","year":"2005","unstructured":"Thorley-Lawson DA (2005) EBV the prototypical human tumor virus - just how bad is it? J Allergy Clin Immunol 116:251\u2013261. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2005.05.038","journal-title":"J Allergy Clin Immunol"},{"key":"219_CR10","doi-asserted-by":"publisher","unstructured":"\u00c1lvaro T, Lejeune M, Salvad\u00f3 MT, et al (2005) Outcome in Hodgkin \u2019 s Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells Outcome in Hodgkin \u2019 s Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells 11:1467\u20131473. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1869","DOI":"10.1158\/1078-0432.CCR-04-1869"},{"key":"219_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2295","volume":"35","author":"M Gotti","year":"2017","unstructured":"Gotti M, Nicola M, Lucioni M, Fiaccadori V, Ferretti V, Sciarra R, Costanza M, Bono E, Molo S, Maffi A, Croci GA, Varettoni M, Frigeni M, Pascutto C, Arcaini L, Bonfichi M, Paulli M, Cazzola M (2017) Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin\u2019s lymphoma. Hematol Oncol 35:296\u2013302. \n                    https:\/\/doi.org\/10.1002\/hon.2295","journal-title":"Hematol Oncol"},{"key":"219_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med 362:875\u2013885. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0905680","journal-title":"N Engl J Med"},{"key":"219_CR13","first-page":"325","volume-title":"WHO classification of Tumours of Haematopoietic and lymphoid tissues, 2017 revis","author":"J Said","year":"2017","unstructured":"Said J, Isaacson PG, Campo E, Harris NL (2017) HHV8-positive germinotropic lymphoproliferative disorder. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of Tumours of Haematopoietic and lymphoid tissues, 2017 revis. IARC, Lyon, pp 325\u2013329"},{"key":"219_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/ajt.13558","volume":"16","author":"J Finalet Ferreiro","year":"2016","unstructured":"Finalet Ferreiro J, Morscio J, Dierickx D, Vandenberghe P, Gheysens O, Verhoef G, Zamani M, Tousseyn T, Wlodarska I (2016) EBV-positive and EBV-negative Posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant 16:414\u2013425. \n                    https:\/\/doi.org\/10.1111\/ajt.13558","journal-title":"Am J Transplant"},{"key":"219_CR15","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","volume":"113","author":"B Chetaille","year":"2009","unstructured":"Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T, Molina T, Vekhoff A, Feugier P, Bouabdallah R, Birnbaum D, Olive D, Xerri L (2009) Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765\u20133775. \n                    https:\/\/doi.org\/10.1182\/blood-2008-07-168096","journal-title":"Blood"},{"key":"219_CR16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ijc.27314","volume":"131","author":"MHM Barros","year":"2012","unstructured":"Barros MHM, Vera-Lozada G, Soares FA, Niedobitek G, Hassan R (2012) Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection. Int J Cancer 131:1142\u20131152. \n                    https:\/\/doi.org\/10.1002\/ijc.27314","journal-title":"Int J Cancer"},{"key":"219_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102977","volume":"9","author":"J Finalet Ferreiro","year":"2014","unstructured":"Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, van der Krogt JA, Michaux L, Shetty S, Krenacs L, Tousseyn T, de Paepe P, Uyttebroeck A, Verhoef G, Taghon T, Vandenberghe P, Cools J, Wlodarska I (2014) Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One 9:e102977. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0102977","journal-title":"PLoS One"},{"key":"219_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.5500\/wjt.v6.i3.505","volume":"6","author":"J Morscio","year":"2016","unstructured":"Morscio J, Tousseyn T (2016) Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders. World J Transplant 6:505. \n                    https:\/\/doi.org\/10.5500\/wjt.v6.i3.505","journal-title":"World J Transplant"},{"key":"219_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13027-018-0186-5","volume":"13","author":"S Giunco","year":"2018","unstructured":"Giunco S, Petrara MR, Zangrossi M, Celeghin A, de Rossi A (2018) Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications. Infect Agent Cancer 13:1\u20137. \n                    https:\/\/doi.org\/10.1186\/s13027-018-0186-5","journal-title":"Infect Agent Cancer"},{"key":"219_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1182\/blood-2007-01-066100","volume":"110","author":"MK Gandhi","year":"2007","unstructured":"Gandhi MK, Moll G, Smith C, Dua U, Lambley E, Ramuz O, Gill D, Marlton P, Seymour JF, Khanna R (2007) Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110:1326\u20131329. \n                    https:\/\/doi.org\/10.1182\/blood-2007-01-066100","journal-title":"Blood"},{"key":"219_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2353\/ajpath.2008.070845","volume":"173","author":"KRN Baumforth","year":"2008","unstructured":"Baumforth KRN, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, Kalk E, Piper K, Lee S, Machado L, Hadley K, Sundblad A, Sjoberg J, Bjorkholm M, Porwit AA, Yap LF, Teo S, Grundy RG, Young LS, Ernberg I, Woodman CBJ, Murray PG (2008) Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin\u2019s lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 173:195\u2013204. \n                    https:\/\/doi.org\/10.2353\/ajpath.2008.070845","journal-title":"Am J Pathol"},{"key":"219_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/path.2384","volume":"216","author":"M Vockerodt","year":"2008","unstructured":"Vockerodt M, Morgan SL, Kuo M, Wei W, Chukwuma MB, Arrand JR, Kube D, Gordon J, Young LS, Woodman CB, Murray PG (2008) The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal Centre B cells towards a Hodgkin\u2019s reed-Sternberg-like phenotype. J Pathol 216:83\u201392. \n                    https:\/\/doi.org\/10.1002\/path.2384","journal-title":"J Pathol"},{"key":"219_CR23","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.4049\/jimmunol.179.12.8225","volume":"179","author":"SL Lambert","year":"2007","unstructured":"Lambert SL, Martinez OM (2007) Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 179:8225\u20138234. \n                    https:\/\/doi.org\/10.4049\/jimmunol.179.12.8225","journal-title":"J Immunol"},{"key":"219_CR24","doi-asserted-by":"publisher","first-page":"16085","DOI":"10.1074\/jbc.274.23.16085","volume":"274","author":"AG Eliopoulos","year":"1999","unstructured":"Eliopoulos AG, Gallagher NJ, Blake SM et al (1999) Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274:16085\u201316096","journal-title":"J Biol Chem"},{"key":"219_CR25","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1128\/JVI.03678-13","volume":"88","author":"W Liu","year":"2014","unstructured":"Liu W, Lin Y, Xiao H, Xing S, Chen H, Chi PD, Zhang G (2014) Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38\/mitogen-activated protein kinase and NF-\u03baB pathways: impairment in T cell functions. J Virol 88:6660\u20136671. \n                    https:\/\/doi.org\/10.1128\/JVI.03678-13","journal-title":"J Virol"},{"key":"219_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1182\/blood-2006-11-059881","volume":"111","author":"JR Flavell","year":"2008","unstructured":"Flavell JR, Baumforth KRN, Wood VHJ, Davies GL, Wei W, Reynolds GM, Morgan S, Boyce A, Kelly GL, Young LS, Murray PG (2008) Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus-encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 111:292\u2013301. \n                    https:\/\/doi.org\/10.1182\/blood-2006-11-059881","journal-title":"Blood"},{"key":"219_CR27","doi-asserted-by":"publisher","unstructured":"Jochum S, Moosmann A, Lang S et al (2012) The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog 8. \n                    https:\/\/doi.org\/10.1371\/journal.ppat.1002704","DOI":"10.1371\/journal.ppat.1002704"},{"key":"219_CR28","doi-asserted-by":"publisher","first-page":"6742","DOI":"10.1093\/emboj\/19.24.6742","volume":"19","author":"N Kitagawa","year":"2000","unstructured":"Kitagawa N, Goto M, Kurozumi K et al (2000) Epstein - Barr virus-encoded poly ( a )- RNA supports Burkitt \u2019 s lymphoma growth through interleukin-10 induction. EMBO J 19:6742\u20136750. \n                    https:\/\/doi.org\/10.1093\/emboj\/19.24.6742","journal-title":"EMBO J"},{"key":"219_CR29","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1128\/JVI.78.4.1665","volume":"78","author":"T Nakayama","year":"2004","unstructured":"Nakayama T, Hieshima K, Nagakubo D, Sato E, Nakayama M, Kawa K, Yoshie O (2004) Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein. J Virol 78:1665\u20131674. \n                    https:\/\/doi.org\/10.1128\/JVI.78.4.1665","journal-title":"J Virol"},{"key":"219_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1006503","volume":"13","author":"TT Cai","year":"2017","unstructured":"Cai TT, Ye SB, Liu YN, He J, Chen QY, Mai HQ, Zhang CX, Cui J, Zhang XS, Busson P, Zeng YX, Li J (2017) LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. PLoS Pathog 13:1\u201323. \n                    https:\/\/doi.org\/10.1371\/journal.ppat.1006503","journal-title":"PLoS Pathog"},{"key":"219_CR31","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1182\/blood-2010-11-320481","volume":"117","author":"J Ouyang","year":"2011","unstructured":"Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA (2011) Viral induction and targeted inhibition of galectin-1 in EBV + posttransplant lymphoproliferative disorders. Blood 117:4315\u20134322. \n                    https:\/\/doi.org\/10.1182\/blood-2010-11-320481","journal-title":"Blood"},{"key":"219_CR32","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","volume":"111","author":"R Yamamoto","year":"2008","unstructured":"Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, Kondo T, Ohmori K, Kurata M, Hayashi T, Uchiyama T (2008) PD-1 PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111:3220\u20133224. \n                    https:\/\/doi.org\/10.1182\/blood-2007-05-085159","journal-title":"Blood"},{"key":"219_CR33","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1073\/pnas.0706017104","volume":"104","author":"P Juszczynski","year":"2007","unstructured":"Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA (2007) The AP1-dependent secretion of galectin-1 by reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci 104:13134\u201313139. \n                    https:\/\/doi.org\/10.1073\/pnas.0706017104","journal-title":"Proc Natl Acad Sci"},{"key":"219_CR34","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-l1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18:1611\u20131618. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1942","journal-title":"Clin Cancer Res"},{"key":"219_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/JLB.2A0118-029RR","volume":"104","author":"MS Gilardini Montani","year":"2018","unstructured":"Gilardini Montani MS, Santarelli R, Falcinelli L, Gonnella R, Granato M, di Renzo L, Cuomo L, Vitillo M, Faggioni A, Cirone M (2018) EBV up-regulates PD-L1 on the surface of primary monocytes by increasing ROS and activating TLR signaling and STAT3. J Leukoc Biol 104:821\u2013832. \n                    https:\/\/doi.org\/10.1002\/JLB.2A0118-029RR","journal-title":"J Leukoc Biol"},{"key":"219_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-3-319-22822-8_12","volume-title":"Epstein Barr Virus Volume 1","author":"P Murray","year":"2015","unstructured":"Murray P, Bell A (2015) Contribution of the Epstein-Barr virus to the pathogenesis of Hodgkin lymphoma. In: M\u00fcnz C (ed) Epstein Barr Virus Volume 1. Springer International Publishing, Cham, pp 287\u2013313"},{"key":"219_CR37","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4049\/jimmunol.0802686","volume":"182","author":"D Li","year":"2009","unstructured":"Li D, Qian L, Chen C, Shi M, Yu M, Hu M, Song L, Shen B, Guo N (2009) Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic Transactivator Zta during Epstein-Barr virus reactivation. J Immunol 182:1799\u20131809. \n                    https:\/\/doi.org\/10.4049\/jimmunol.0802686","journal-title":"J Immunol"},{"key":"219_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.virusres.2006.02.008","volume":"119","author":"M Savard","year":"2006","unstructured":"Savard M, Gosselin J (2006) Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes. Virus Res 119:134\u2013145. \n                    https:\/\/doi.org\/10.1016\/j.virusres.2006.02.008","journal-title":"Virus Res"},{"key":"219_CR39","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1128\/JVI.74.6.2612-2619.2000","volume":"74","author":"M Savard","year":"2000","unstructured":"Savard M, B\u00e9langer C, Tardif M et al (2000) Infection of primary human monocytes by Epstein-Barr virus. J Virol 74:2612\u20132619. \n                    https:\/\/doi.org\/10.1128\/JVI.74.6.2612-2619.2000","journal-title":"J Virol"},{"key":"219_CR40","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1084\/jem.20081761","volume":"206","author":"D Iwakiri","year":"2009","unstructured":"Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, Imai S, Fujieda M, Kawa K, Takada K (2009) Epstein-Barr virus (EBV)\u2013encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3. J Exp Med 206:2091\u20132099. \n                    https:\/\/doi.org\/10.1084\/jem.20081761","journal-title":"J Exp Med"},{"key":"219_CR41","doi-asserted-by":"publisher","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","volume":"113","author":"M Albanese","year":"2016","unstructured":"Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W (2016) Epstein\u2013Barr virus microRNAs reduce immune surveillance by virus-specific CD8 + T cells. Proc Natl Acad Sci 113:E6467\u2013E6475. \n                    https:\/\/doi.org\/10.1073\/pnas.1605884113","journal-title":"Proc Natl Acad Sci"},{"key":"219_CR42","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1084\/jem.20160248","volume":"213","author":"T Tagawa","year":"2016","unstructured":"Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, Zielinski C, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Hammerschmidt W (2016) Epstein-Barr viral miRNAs inhibit antiviral CD4 + T cell responses targeting IL-12 and peptide processing. J Exp Med 213:2065\u20132080. \n                    https:\/\/doi.org\/10.1084\/jem.20160248","journal-title":"J Exp Med"},{"key":"219_CR43","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/cancers6031615","volume":"6","author":"D Iwakiri","year":"2014","unstructured":"Iwakiri D (2014) Epstein-Barr virus-encoded RNAs: key molecules in viral pathogenesis. Cancers (Basel) 6:1615\u20131630. \n                    https:\/\/doi.org\/10.3390\/cancers6031615","journal-title":"Cancers (Basel)"},{"key":"219_CR44","unstructured":"Hawthorne DC, Leupold U, Allday MJ, et al (2015) Epstein Barr Virus Volume 2. Springer International Publishing, Cham"},{"key":"219_CR45","unstructured":"Allday MJ, Bazot Q, White RE (2015) Epstein Barr Virus Volume 2. Springer International Publishing, Cham"},{"key":"219_CR46","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1097\/TP.0000000000001767","volume":"101","author":"OM Martinez","year":"2017","unstructured":"Martinez OM, Krams SM (2017) The immune response to Epstein Barr virus and implications for posttransplant lymphoproliferative disorder. Transplantation 101:2009\u20132016. \n                    https:\/\/doi.org\/10.1097\/TP.0000000000001767","journal-title":"Transplantation"},{"key":"219_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2015.04.006","volume":"34","author":"R Dolcetti","year":"2015","unstructured":"Dolcetti R (2015) Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas. Semin Cancer Biol 34:58\u201369. \n                    https:\/\/doi.org\/10.1016\/j.semcancer.2015.04.006","journal-title":"Semin Cancer Biol"},{"key":"219_CR48","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/viro.2002.1716","volume":"304","author":"S Salek-Ardakani","year":"2002","unstructured":"Salek-Ardakani S, Arrand JR, Mackett M (2002) Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV. Virology 304:342\u2013351. \n                    https:\/\/doi.org\/10.1006\/viro.2002.1716","journal-title":"Virology"},{"key":"219_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1349-7006.2009.01377.x","volume":"101","author":"M Samanta","year":"2010","unstructured":"Samanta M, Takada K (2010) Modulation of innate immunity system by Epstein-Barr virus-encoded non-coding RNA and oncogenesis. Cancer Sci 101:29\u201335. \n                    https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01377.x","journal-title":"Cancer Sci"},{"key":"219_CR50","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.4049\/jimmunol.165.10.5729","volume":"165","author":"MK Maini","year":"2000","unstructured":"Maini MK, Gudgeon N, Wedderburn LR, Rickinson AB, Beverley PCL (2000) Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J Immunol 165:5729\u20135737. \n                    https:\/\/doi.org\/10.4049\/jimmunol.165.10.5729","journal-title":"J Immunol"},{"key":"219_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/(SICI)1096-9896(199802)184:2<177::AID-PATH977>3.0.CO;2-C","volume":"184","author":"SM Perera","year":"1998","unstructured":"Perera SM, Thomas JA, Burke M, Crawford DH (1998) Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J Pathol 184:177\u2013184. \n                    https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199802)184:2<177::AID-PATH977>3.0.CO;2-C","journal-title":"J Pathol"},{"key":"219_CR52","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1182\/blood-2006-05-023663","volume":"109","author":"KN Heller","year":"2007","unstructured":"Heller KN, Upshaw J, Seyoum B, Zebroski H, Munz C (2007) Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 109:1138\u20131146. \n                    https:\/\/doi.org\/10.1182\/blood-2006-05-023663","journal-title":"Blood"},{"key":"219_CR53","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/00007890-200205270-00014","volume":"73","author":"F Smets","year":"2002","unstructured":"Smets F, Latinne D, Bazin H et al (2002) Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73:1603\u20131610","journal-title":"Transplantation"},{"key":"219_CR54","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1158\/1078-0432.CCR-12-2537","volume":"19","author":"S Giunco","year":"2013","unstructured":"Giunco S, Dolcetti R, Keppel S, Celeghin A, Indraccolo S, Dal Col J, Mastorci K, de Rossi A (2013) hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies. Clin Cancer Res 19:2036\u20132047. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2537","journal-title":"Clin Cancer Res"},{"key":"219_CR55","doi-asserted-by":"publisher","first-page":"10175","DOI":"10.1128\/JVI.00321-08","volume":"82","author":"L Terrin","year":"2008","unstructured":"Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G, Bergamin S, Rizzo S, Dolcetti R, de Rossi A (2008) Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol 82:10175\u201310187. \n                    https:\/\/doi.org\/10.1128\/JVI.00321-08","journal-title":"J Virol"},{"key":"219_CR56","doi-asserted-by":"crossref","first-page":"1617 LP","DOI":"10.1182\/blood.V124.21.1617.1617","volume":"124","author":"M\u00d8 Vase","year":"2014","unstructured":"Vase M\u00d8, Maksten E, Bendix K et al (2014) Tumor microenvironmental features and outcome in post-transplant lymphoproliferative disorder. Blood 124:1617 LP\u20131611617","journal-title":"Blood"},{"key":"219_CR57","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/blood-2002-01-0099.BLOOD","volume":"77","author":"BF Skinnider","year":"2002","unstructured":"Skinnider BF, Mak TW, Houston JP et al (2002) Review article the role of cytokines in classical Hodgkin lymphoma. Cytometry A 77:861\u2013872. \n                    https:\/\/doi.org\/10.1182\/blood-2002-01-0099.BLOOD","journal-title":"Cytometry A"},{"key":"219_CR58","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/ijc.23119","volume":"122","author":"D Aldinucci","year":"2008","unstructured":"Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, Colombatti A (2008) Expression of CCR5 receptors on reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 122:769\u2013776. \n                    https:\/\/doi.org\/10.1002\/ijc.23119","journal-title":"Int J Cancer"},{"key":"219_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.11370","volume":"107","author":"M Fischer","year":"2003","unstructured":"Fischer M, Juremalm M, Olsson N, Backlin C, Sundstr\u00f6m C, Nilsson K, Enblad G, Nilsson G (2003) Expression of CCL5\/RANTES by Hodgkin and reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 107:197\u2013201. \n                    https:\/\/doi.org\/10.1002\/ijc.11370","journal-title":"Int J Cancer"},{"key":"219_CR60","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","volume":"154","author":"A Berg van den","year":"1999","unstructured":"van den Berg A, Visser L, Poppema S (1999) High expression of the CC chemokine TARC in reed-Sternberg cells. Am J Pathol 154:1685\u20131691. \n                    https:\/\/doi.org\/10.1016\/S0002-9440(10)65424-7","journal-title":"Am J Pathol"},{"key":"219_CR61","doi-asserted-by":"publisher","unstructured":"Kinch A, Sundstr\u00f6m C, Baecklund E, Backlin C, Molin D, Enblad G (2018) Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. Leuk Lymphoma:1\u20139. \n                    https:\/\/doi.org\/10.1080\/10428194.2018.1480767","DOI":"10.1080\/10428194.2018.1480767"},{"key":"219_CR62","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, Yu H, Fletcher CDM, Freeman GJ, Shipp MA, Rodig SJ (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19:3462\u20133473. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0855","journal-title":"Clin Cancer Res"},{"key":"219_CR63","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/modpathol.2016.199","volume":"30","author":"J Morscio","year":"2017","unstructured":"Morscio J, Finalet Ferreiro J, Vander Borght S, Bittoun E, Gheysens O, Dierickx D, Verhoef G, Wlodarska I, Tousseyn T (2017) Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma. Mod Pathol 30:370\u2013381. \n                    https:\/\/doi.org\/10.1038\/modpathol.2016.199","journal-title":"Mod Pathol"},{"key":"219_CR64","doi-asserted-by":"publisher","first-page":"24148","DOI":"10.1074\/jbc.M109036200","volume":"277","author":"M Tardif","year":"2002","unstructured":"Tardif M, Savard M, Flamand L, Gosselin J (2002) Impaired protein kinase C activation\/translocation in Epstein-Barr virus-infected monocytes. J Biol Chem 277:24148\u201324154. \n                    https:\/\/doi.org\/10.1074\/jbc.M109036200","journal-title":"J Biol Chem"},{"key":"219_CR65","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/emboj\/21.5.954","volume":"21","author":"A Nanbo","year":"2002","unstructured":"Nanbo A, Inoue K, Adachi-Takasawa K, Takada K (2002) Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt\u2019s lymphoma. EMBO J 21:954\u2013965. \n                    https:\/\/doi.org\/10.1093\/emboj\/21.5.954","journal-title":"EMBO J"},{"key":"219_CR66","doi-asserted-by":"publisher","unstructured":"Yang L, Aozasa K, Oshimi K, Takada K (2004) Epstein-Barr virus ( EBV ) -encoded RNA promotes growth of EBV-infected T cells through Interleukin-9 induction Epstein-Barr virus ( EBV ) -encoded RNA promotes growth of EBV-infected T cells through Interleukin-9 induction. 5332\u20135337. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0733","DOI":"10.1158\/0008-5472.CAN-04-0733"},{"key":"219_CR67","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/1471-2407-6-283","volume":"6","author":"C Keryer-Bibens","year":"2006","unstructured":"Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souqu\u00e8re S, Nishi N, Hirashima M, Middeldorp J, Busson P (2006) Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6:283. \n                    https:\/\/doi.org\/10.1186\/1471-2407-6-283","journal-title":"BMC Cancer"},{"key":"219_CR68","doi-asserted-by":"publisher","unstructured":"M\u00fcnz C, Chijioke O (2017) Natural killer cells in herpesvirus infections. F1000Research 6:1231. \n                    https:\/\/doi.org\/10.12688\/f1000research.11197.1","DOI":"10.12688\/f1000research.11197.1"},{"key":"219_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.01658","volume":"8","author":"C M\u00fcnz","year":"2017","unstructured":"M\u00fcnz C (2017) Epstein-Barr virus-specific immune control by innate lymphocytes. Front Immunol 8:1\u20137. \n                    https:\/\/doi.org\/10.3389\/fimmu.2017.01658","journal-title":"Front Immunol"},{"key":"219_CR70","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.4049\/jimmunol.1301046","volume":"191","author":"A Lunemann","year":"2013","unstructured":"Lunemann A, Vanoaica LD, Azzi T, Nadal D, Munz C (2013) A distinct subpopulation of human NK cells restricts B cell transformation by EBV. J Immunol 191:4989\u20134995. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1301046","journal-title":"J Immunol"},{"key":"219_CR71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/pathogens7020040","volume":"7","author":"G Tan","year":"2018","unstructured":"Tan G, Visser L, Tan L, Berg A, Diepstra A (2018) The microenvironment in Epstein\u2013Barr virus-associated malignancies. Pathogens 7:40. \n                    https:\/\/doi.org\/10.3390\/pathogens7020040","journal-title":"Pathogens"},{"key":"219_CR72","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","volume":"66","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66:5716\u20135722. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0261","journal-title":"Cancer Res"},{"key":"219_CR73","doi-asserted-by":"publisher","unstructured":"Wu R, Sattarzadeh A, Rutgers B, Diepstra A, van den Berg A, Visser L (2016) The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor. Blood Cancer J 6. \n                    https:\/\/doi.org\/10.1038\/bcj.2016.26","DOI":"10.1038\/bcj.2016.26"},{"key":"219_CR74","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/bjh.12980","volume":"166","author":"O Morales","year":"2014","unstructured":"Morales O, Mrizak D, Fran\u00e7ois V, Mustapha R, Miroux C, Depil S, Decouvelaere AV, Lionne-Huyghe P, Auriault C, de Launoit Y, Pancr\u00e9 V, Delhem N (2014) Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. Br J Haematol 166:875\u2013890. \n                    https:\/\/doi.org\/10.1111\/bjh.12980","journal-title":"Br J Haematol"},{"key":"219_CR75","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1007\/s12032-012-0299-4","volume":"29","author":"MCG Assis","year":"2012","unstructured":"Assis MCG, Campos AHFM, Oliveira JSR, Soares FA, Silva JMK, Silva PB, Penna AD, Souza EM, Baiocchi OCG (2012) Increased expression of CD4+CD25+FOXP3+ regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil. Med Oncol 29:3614\u20133619. \n                    https:\/\/doi.org\/10.1007\/s12032-012-0299-4","journal-title":"Med Oncol"},{"key":"219_CR76","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","volume":"108","author":"MK Gandhi","year":"2006","unstructured":"Gandhi MK, Lambley E, Duraiswamy J et al (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108:2280\u20132289. \n                    https:\/\/doi.org\/10.1182\/blood-2006-04-015164","journal-title":"Blood"},{"key":"219_CR77","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1002\/ijc.25597","volume":"128","author":"PH Braz-Silva","year":"2011","unstructured":"Braz-Silva PH, Vitale S, Butori C, Guevara N, Santini J, Magalh\u00e3es M, Hofman P, Doglio A (2011) Specific infiltration of langerin-positive dendritic cells in EBV-infected tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma. Int J Cancer 128:2501\u20132508. \n                    https:\/\/doi.org\/10.1002\/ijc.25597","journal-title":"Int J Cancer"},{"key":"219_CR78","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-12-0129","volume":"18","author":"MHM Barros","year":"2012","unstructured":"Barros MHM, Hassan R, Niedobitek G et al (2012) Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res 18:3762\u20133771. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0129","journal-title":"Clin Cancer Res"},{"key":"219_CR79","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2010.031542","volume":"96","author":"P Kamper","year":"2011","unstructured":"Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin\u2019s lymphoma. Haematologica 96:269\u2013276. \n                    https:\/\/doi.org\/10.3324\/haematol.2010.031542","journal-title":"Haematologica"},{"key":"219_CR80","unstructured":"Swerdlow SH, Campo E, Harris NL, et al (2008) WHO classification of Tumours of Haematopoietic and lymphoid tissues, revised fourth edition, revised 4t. World Health Organization"},{"key":"219_CR81","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","volume":"126","author":"A Nicolae","year":"2015","unstructured":"Nicolae A, Pittaluga S, Abdullah S, Steinberg SM, Pham TA, Davies-Hill T, Xi L, Raffeld M, Jaffe ES (2015) EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 126:863\u2013872. \n                    https:\/\/doi.org\/10.1182\/blood-2015-02-630632","journal-title":"Blood"},{"key":"219_CR82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","volume":"105","author":"G Pawelec","year":"2018","unstructured":"Pawelec G (2018) Age and immunity: what is \u201cimmunosenescence\u201d? Exp Gerontol 105:4\u20139. \n                    https:\/\/doi.org\/10.1016\/j.exger.2017.10.024","journal-title":"Exp Gerontol"},{"key":"219_CR83","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/neup.12435","volume":"38","author":"Y Sugita","year":"2017","unstructured":"Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M, Abe H, Nozawa T, Fujii Y, Takahashi H, Kakita A (2017) The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: the role of programmed cell death 1 and programmed cell death ligand 1. Neuropathology 38:125\u2013134. \n                    https:\/\/doi.org\/10.1111\/neup.12435","journal-title":"Neuropathology"},{"key":"219_CR84","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2217\/bmm.15.13","volume":"9","author":"JG Taylor","year":"2015","unstructured":"Taylor JG, Liapis K, Gribben JG (2015) The role of the tumor microenvironment in HIV-associated lymphomas. Biomark Med 9:473\u2013482. \n                    https:\/\/doi.org\/10.2217\/bmm.15.13","journal-title":"Biomark Med"},{"key":"219_CR85","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1084\/jem.20081398","volume":"205","author":"RB Jones","year":"2008","unstructured":"Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, Nixon DF, Ostrowski MA (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205:2763\u20132779. \n                    https:\/\/doi.org\/10.1084\/jem.20081398","journal-title":"J Exp Med"},{"key":"219_CR86","doi-asserted-by":"publisher","unstructured":"Buggert M, Nguyen S, Salgado-Montes de Oca G, Bengsch B, Darko S, Ransier A, Roberts ER, del Alcazar D, Brody IB, Vella LA, Beura L, Wijeyesinghe S, Herati RS, del Rio Estrada PM, Ablanedo-Terrazas Y, Kuri-Cervantes L, Sada Japp A, Manne S, Vartanian S, Huffman A, Sandberg JK, Gostick E, Nadolski G, Silvestri G, Canaday DH, Price DA, Petrovas C, Su LF, Vahedi G, Dori Y, Frank I, Itkin MG, Wherry EJ, Deeks SG, Naji A, Reyes-Ter\u00e1n G, Masopust D, Douek DC, Betts MR (2018) Identification and characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue. Sci Immunol 3. \n                    https:\/\/doi.org\/10.1126\/sciimmunol.aar4526","DOI":"10.1126\/sciimmunol.aar4526"},{"key":"219_CR87","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2015.06.002","volume":"34","author":"L Pantanowitz","year":"2015","unstructured":"Pantanowitz L, Carbone A, Dolcetti R (2015) Microenvironment and HIV-related lymphomagenesis. Semin Cancer Biol 34:52\u201357. \n                    https:\/\/doi.org\/10.1016\/j.semcancer.2015.06.002","journal-title":"Semin Cancer Biol"},{"key":"219_CR88","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486\u2013499. \n                    https:\/\/doi.org\/10.1038\/nri3862","journal-title":"Nat Rev Immunol"},{"key":"219_CR89","doi-asserted-by":"publisher","unstructured":"Davoodzadeh Gholami M, kardar GA, Saeedi Y, et al (2017) Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol 322:1\u201314. \n                    https:\/\/doi.org\/10.1016\/j.cellimm.2017.10.002","DOI":"10.1016\/j.cellimm.2017.10.002"},{"key":"219_CR90","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20061496","volume":"203","author":"C Petrovas","year":"2006","unstructured":"Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC, Koup RA (2006) PD-1 is a regulator of virus-specific CD8 + T cell survival in HIV infection. J Exp Med 203:2281\u20132292. \n                    https:\/\/doi.org\/10.1084\/jem.20061496","journal-title":"J Exp Med"},{"key":"219_CR91","doi-asserted-by":"crossref","unstructured":"Kaufmann DE, Walker BD (2008) Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. Curr Opin HIV AIDS 3:","DOI":"10.1097\/COH.0b013e3282f9ae8b"},{"key":"219_CR92","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1084\/jem.20101773","volume":"208","author":"LM Fahey","year":"2011","unstructured":"Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG (2011) Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J Exp Med 208:987\u2013999. \n                    https:\/\/doi.org\/10.1084\/jem.20101773","journal-title":"J Exp Med"},{"key":"219_CR93","doi-asserted-by":"publisher","first-page":"0790","DOI":"10.1371\/journal.pmed.0050100","volume":"5","author":"H Streeck","year":"2008","unstructured":"Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, Brumme CJ, Rosenberg ES, Alter G, Allen TM, Walker BD, Altfeld M (2008) Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 5:0790\u20130803. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.0050100","journal-title":"PLoS Med"},{"key":"219_CR94","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/petr.12156","volume":"17","author":"J Moran","year":"2013","unstructured":"Moran J, Dean J, De Oliveira A et al (2013) Increased levels of PD-1 expression on CD8 T cells in patients post-renal transplant irrespective of chronic high EBV viral load. Pediatr Transplant 17:806\u2013814. \n                    https:\/\/doi.org\/10.1111\/petr.12156","journal-title":"Pediatr Transplant"},{"key":"219_CR95","doi-asserted-by":"publisher","first-page":"10813","DOI":"10.1038\/s41598-017-11052-z","volume":"7","author":"M Cohen","year":"2017","unstructured":"Cohen M, Vistarop AG, Huaman F, Narbaitz M, Metrebian F, de Matteo E, Preciado MV, Chabay PA (2017) Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact. Sci Rep 7:10813. \n                    https:\/\/doi.org\/10.1038\/s41598-017-11052-z","journal-title":"Sci Rep"},{"key":"219_CR96","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.lungcan.2011.10.001","volume":"76","author":"L Boehmer Von","year":"2012","unstructured":"Von Boehmer L, Draenert A, Jungraithmayr W et al (2012) Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. Lung Cancer 76:118\u2013122. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2011.10.001","journal-title":"Lung Cancer"},{"key":"219_CR97","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1432-2277.2012.01451.x","volume":"25","author":"L Bererhi","year":"2012","unstructured":"Bererhi L, Pallet N, Zuber J, Anglicheau D, Kreis H, Legendre C, Candon S (2012) Clinical and immunological features of very long-term survivors with a single renal transplant. Transpl Int 25:545\u2013554. \n                    https:\/\/doi.org\/10.1111\/j.1432-2277.2012.01451.x","journal-title":"Transpl Int"},{"key":"219_CR98","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","volume":"71","author":"DE Tsai","year":"2001","unstructured":"Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076\u20131088","journal-title":"Transplantation"},{"key":"219_CR99","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","volume":"126","author":"D Dierickx","year":"2015","unstructured":"Dierickx D, Tousseyn T, Gheysens O (2015) How I treat how I treat posttransplant lymphoproliferative disorders case reports. Blood 126:2274\u20132284. \n                    https:\/\/doi.org\/10.1182\/blood-2015-05-615872","journal-title":"Blood"},{"key":"219_CR100","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.trim.2012.02.001","volume":"27","author":"FL Pietersma","year":"2012","unstructured":"Pietersma FL, van Oosterom A, Ran L, Schuurman R, Meijer E, de Jonge N, van Baarle D (2012) Adequate control of primary EBV infection and subsequent reactivations after cardiac transplantation in an EBV seronegative patient. Transpl Immunol 27:48\u201351. \n                    https:\/\/doi.org\/10.1016\/j.trim.2012.02.001","journal-title":"Transpl Immunol"},{"key":"219_CR101","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/00007890-200208270-00012","volume":"74","author":"D a Falco","year":"2002","unstructured":"Falco D a, Nepomuceno RR, Krams SM et al (2002) Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 74:501\u2013510","journal-title":"Transplantation"},{"key":"219_CR102","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3109\/10428190903315713","volume":"50","author":"BG Richendollar","year":"2009","unstructured":"Richendollar BG, Tsao RE, Elson P, Jin T, Steinle R, Pohlman B, Hsi ED (2009) Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk Lymphoma 50:2005\u20132012. \n                    https:\/\/doi.org\/10.3109\/10428190903315713","journal-title":"Leuk Lymphoma"},{"key":"219_CR103","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trim.2009.02.002","volume":"21","author":"M Calvo-Turrubiartes","year":"2009","unstructured":"Calvo-Turrubiartes M, Romano-Moreno S, Garc\u00eda-Hern\u00e1ndez M, Chevaile-Ramos JA, Layseca-Espinosa E, Gonz\u00e1lez-Amaro R, Portales-P\u00e9rez D (2009) Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level. Transpl Immunol 21:43\u201349. \n                    https:\/\/doi.org\/10.1016\/j.trim.2009.02.002","journal-title":"Transpl Immunol"},{"key":"219_CR104","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.transproceed.2018.01.001","volume":"50","author":"MA Carmona-Escamilla","year":"2018","unstructured":"Carmona-Escamilla MA, Queipo G, Garc\u00eda-Mosqueda LA, Garc\u00eda-Covarrubias L, Fonseca-S\u00e1nchez MA, Villanueva-Ortega E, Prieto P, Lascurain R (2018) Peripheral blood regulatory T cells are diminished in kidney transplant patients with chronic allograft nephropathy. Transplant Proc 50:444\u2013448. \n                    https:\/\/doi.org\/10.1016\/j.transproceed.2018.01.001","journal-title":"Transplant Proc"},{"key":"219_CR105","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1978::AID-CNCR23>3.0.CO;2-P","volume":"82","author":"A Chadburn","year":"1998","unstructured":"Chadburn A, Chen JM, Hsu DT, Frizzera G, Cesarman E, Garrett TJ, Mears JG, Zangwill SD, Addonizio LJ, Michler RE, Knowles DM (1998) The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 82:1978\u20131987. \n                    https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19980515)82:10<1978::AID-CNCR23>3.0.CO;2-P","journal-title":"Cancer"},{"key":"219_CR106","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1309\/AJCPQYYE04AVGVYI","volume":"138","author":"BP Nelson","year":"2012","unstructured":"Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M (2012) Early posttransplant lymphoproliferative disease. Am J Clin Pathol 138:568\u2013578. \n                    https:\/\/doi.org\/10.1309\/AJCPQYYE04AVGVYI","journal-title":"Am J Clin Pathol"},{"key":"219_CR107","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hon.859","volume":"26","author":"E Vakiani","year":"2008","unstructured":"Vakiani E, Basso K, Klein U, Mansukhani MM, Narayan G, Smith PM, Murty VV, Dalla-Favera R, Pasqualucci L, Bhagat G (2008) Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol 26:199\u2013211. \n                    https:\/\/doi.org\/10.1002\/hon.859","journal-title":"Hematol Oncol"},{"key":"219_CR108","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1365-2559.2011.03872.x","volume":"59","author":"HAH Ibrahim","year":"2011","unstructured":"Ibrahim HAH, Menasce L, Pomplun S et al (2011) Tumour infiltrating plasmacytoid dendritic cells in B cell post-transplant lymphoproliferative disorders, human immunodeficiency virus-associated B cell lymphomas and immune competent diffuse large B cell lymphomas. Histopathology 59:152\u2013156. \n                    https:\/\/doi.org\/10.1111\/j.1365-2559.2011.03872.x","journal-title":"Histopathology"},{"key":"219_CR109","first-page":"876","volume":"67","author":"SA Birkeland","year":"1999","unstructured":"Birkeland SA, Bendtzen K, M\u00f8ller B et al (1999) Interleukin-10 and Posttransplant lymphoproliferative disorder after kidney transplantation. Immunobiology 67:876\u2013881","journal-title":"Immunobiology"},{"key":"219_CR110","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1046\/j.1365-2141.2003.04540.x","volume":"122","author":"G Muti","year":"2003","unstructured":"Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, Gatti M, Gargantini L, Caramella M, Mancini V, Gerna G, Morra E, for the Co-operative Study Group on PTLDs* (2003) Epstein \u2013 Barr virus ( EBV ) load and interleukin-10 in lymphoproliferative disorders. Br J Haematol 122:927\u2013933","journal-title":"Br J Haematol"},{"key":"219_CR111","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0046-8177(96)90369-X","volume":"27","author":"TT Wu","year":"1996","unstructured":"Wu TT, Swerdlow SH, Locker J, Bahler D, Randhawa P, Yunis EJ, Dickman PS, Nalesnik MA (1996) Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients. Hum Pathol 27:157\u2013164. \n                    https:\/\/doi.org\/10.1016\/S0046-8177(96)90369-X","journal-title":"Hum Pathol"},{"key":"219_CR112","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","volume":"54","author":"D Dierickx","year":"2013","unstructured":"Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, Brepoels L, Kuypers D, Vanhaecke J, Nevens F, Verleden G, van Damme-Lombaerts R, Renard M, Pirenne J, de Wolf-Peeters C, Verhoef G (2013) Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 54:2433\u20132440. \n                    https:\/\/doi.org\/10.3109\/10428194.2013.780655","journal-title":"Leuk Lymphoma"},{"key":"219_CR113","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.3324\/haematol.2015.124305","volume":"100","author":"JF Ferreiro","year":"2015","unstructured":"Ferreiro JF, Morscio J, Dierickx D, Marcelis L, Verhoef G, Vandenberghe P, Tousseyn T, Wlodarska I (2015) Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain\/loss pattern. Haematologica 100:e275\u2013e279. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.124305","journal-title":"Haematologica"},{"key":"219_CR114","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3109\/10428194.2013.775436","volume":"54","author":"A Herreman","year":"2013","unstructured":"Herreman A, Dierickx D, Morscio J, Camps J, Bittoun E, Verhoef G, de Wolf-Peeters C, Sagaert X, Tousseyn T (2013) Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma 54:2190\u20132199. \n                    https:\/\/doi.org\/10.3109\/10428194.2013.775436","journal-title":"Leuk Lymphoma"},{"key":"219_CR115","doi-asserted-by":"crossref","unstructured":"Morscio J, Dierickx D, Ferreiro JF, Herreman A, Van Loo P, Bittoun E, Verhoef G, Matthys P, Cools J, Wlodarska I, De Wolf-Peeters C, Sagaert X, Tousseyn T (2013) Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 13(5):1305\u20131316","DOI":"10.1111\/ajt.12196"},{"key":"219_CR116","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12288-017-0799-7","volume":"33","author":"L Fu","year":"2017","unstructured":"Fu L, Xie J, Lin J, Wang J, Wei N, Huang D, Wang T, Shen J, Zhou X, Wang Z (2017) Monomorphic post-transplant lymphoproliferative disorder after kidney transplantation and hematopoietic stem cell transplantation: Clinicopathological characteristics, treatments and prognostic factors. Indian J Hematol Blood Transfus 33:492\u2013499. \n                    https:\/\/doi.org\/10.1007\/s12288-017-0799-7","journal-title":"Indian J Hematol Blood Transfus"},{"key":"219_CR117","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2010.33.4623","volume":"29","author":"J Brody","year":"2011","unstructured":"Brody J, Kohrt H, Marabelle A, Levy R (2011) Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol 29:1864\u20131875. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.33.4623","journal-title":"J Clin Oncol"},{"key":"219_CR118","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1056\/NEJMc1614298","volume":"376","author":"R Barnett","year":"2017","unstructured":"Barnett R, Barta VS, Jhaveri KD (2017) Preserved renal-allograft function and the PD-1 pathway inhibitor Nivolumab. N Engl J Med 376:191\u2013192. \n                    https:\/\/doi.org\/10.1056\/NEJMc1614298","journal-title":"N Engl J Med"},{"key":"219_CR119","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","volume":"109","author":"SP Perrine","year":"2007","unstructured":"Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV (2007) A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109:2571\u20132578. \n                    https:\/\/doi.org\/10.1182\/blood-2006-01-024703","journal-title":"Blood"},{"key":"219_CR120","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DAA (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80\u201396. \n                    https:\/\/doi.org\/10.1111\/imr.12519","journal-title":"Immunol Rev"},{"key":"219_CR121","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","volume":"15","author":"I Melero","year":"2015","unstructured":"Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15:457\u2013472. \n                    https:\/\/doi.org\/10.1038\/nrc3973","journal-title":"Nat Rev Cancer"},{"key":"219_CR122","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson EJ, Bagnasco SM, Moore J et al (2016) Tumor regression and allograft rejection after Administration of Anti-PD-1. N Engl J Med 374:896\u2013898. \n                    https:\/\/doi.org\/10.1056\/NEJMc1509268","journal-title":"N Engl J Med"},{"key":"219_CR123","first-page":"427","volume-title":"M\u00fcnz C (ed)","author":"S Gottschalk","year":"2015","unstructured":"Gottschalk S, Rooney CM (2015) Adoptive T-cell immunotherapy BT - Epstein Barr virus volume 2: one herpes virus: many diseases. In: M\u00fcnz C (ed). Springer International Publishing, Cham, pp 427\u2013454"},{"key":"219_CR124","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/hum.1994.5.3-381","volume":"5","author":"HE Heslop","year":"1994","unstructured":"Heslop HE, Brenner MK, Rooney C, Krance RA, Roberts WM, Rochester R, Smith CA, Turner V, Sixbey J, Moen R, Boyett JM (1994) Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther 5:381\u2013397. \n                    https:\/\/doi.org\/10.1089\/hum.1994.5.3-381","journal-title":"Hum Gene Ther"},{"key":"219_CR125","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Ng CYC, Loftin S, Smith CA, Li C, Krance RA, Brenner MK, Heslop HE, Rooney CM, Brenner MK, Brenner MK, Krance RA, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9\u201313. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(95)91150-2","journal-title":"Lancet"},{"key":"219_CR126","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1128\/JVI.01777-06","volume":"81","author":"IY Pappworth","year":"2007","unstructured":"Pappworth IY, Wang EC, Rowe M (2007) The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 81:474\u2013482. \n                    https:\/\/doi.org\/10.1128\/JVI.01777-06","journal-title":"J Virol"}],"container-title":["Cancer Microenvironment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12307-018-00219-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12307-018-00219-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12307-018-00219-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T19:21:12Z","timestamp":1579807272000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12307-018-00219-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1007\/s12307-018-00219-5","relation":{},"ISSN":["1875-2292","1875-2284"],"issn-type":[{"value":"1875-2292","type":"print"},{"value":"1875-2284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}